Status: Not yet recruiting
IL-15 Enhanced NK Cell Therapy for Solid Tumors
A single-arm, Phase 1 study evaluating safety, tolerability, and preliminary efficacy of IL-15 enhanced engineered NK cells in patients with refractory relapsed or metastatic solid tumors.
Participants needed: 12
Trial details
Phase: Early Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: Genovn Therapeutics (Suzhou) Co., Ltd.Updated: Jun 2, 2026Locations: 1
Eligibility criteria
Age 18-70 years; [+7]
Pregnancy/lactation; [+10]